吉木 優

Medicine & Life Sciences

1. Percutaneous Coronary Intervention 100%
2. umirolimus 94%
3. Stents 86%
4. alirocumab 84%
5. Equivalence Trials 66%
6. Rivaroxaban 65%
7. Acute Coronary Syndrome 50%
8. Cardiology 49%
9. Aspirin 46%
10. Coronary Vessels 41%
11. Registries 39%
12. Ultrasonography 38%
13. Equipment and Supplies 36%
14. Cardiovascular Diseases 36%
15. Light 35%
16. Lipids 32%
17. Intra-Aortic Balloon Pumping 32%
18. Coronary Artery Disease 30%
19. Atherosclerotic Plaques 26%
20. Extracorporeal Membrane Oxygenation 21%
21. Area Under Curve 20%
22. Sensitivity and Specificity 18%
23. Hemorrhage 16%
24. Placebos 15%
25. Myocardial Infarction 12%
26. Hydroxymethylglutaryl-CoA Reductase Inhibitors 11%
27. Confidence Intervals 11%
28. LDL Cholesterol 10%
29. Vascular Diseases 6%
30. Hospital Mortality 6%
31. Proprotein Convertase 9 5%
32. Hospitalization 5%
33. Random Allocation 5%
34. Injection Site Reaction 5%